Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Amylin is a naturally occurring neuroendocrine hormone synthesized by pancreatic beta cells that contribute to glucose control during the post-prandial period. Amylin is deficient in those with type 1 diabetes and relatively deficient in those with type 2 diabetes. Amylin is collocated with insulin in secretory granules and cosecreted with insulin by pancreatic beta cells in response to food intake. Amylin affects the rate of postprandial glucose appearance by slowing gastric emptying, regulates postprandial glucagon, and reduces food intake caused by centrally mediated modulation of appetite. In addition, amylin suppresses glucagon secretion, which leads to suppression of endogenous glucose output from the liver. Symlin (pramlintide) is a synthetic analog of human amylin used as adjunctive treatment for type 1 or type 2 diabetic participants who use mealtime insulin therapy and have failed to achieve optimal glucose control. It is a stable, soluble, non-aggregating, and equipotent amylin analog that is administered subcutaneously with a meal. This medication acts like amylin and controls glucose levels without causing weight gain. It also regulates postprandial glucose levels by slowing gastric emptying, promoting satiety, and suppressing the abnormal postprandial rise of glucagon in participants with diabetes. Pramlintide also has been shown to not cause hypoglycemia. The most common adverse effect is mild to moderate nausea that generally goes away after 4 weeks of therapy, and the risk of this may be reduced by titrating up the dose more slowly.

Total program savings for the PDL classes will be regularly reviewed.

<table>
<thead>
<tr>
<th>Program-Specific Information:</th>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Criteria:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Increased risk of ADE</td>
<td>☒ Preferred Drug List</td>
<td></td>
</tr>
<tr>
<td>☐ Appropriate Indications</td>
<td>☐ Clinical Edit</td>
<td></td>
</tr>
<tr>
<td><strong>Data Sources:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Only Administrative Databases</td>
<td>☒ Databases + Prescriber-Supplied</td>
<td></td>
</tr>
</tbody>
</table>

SmartPA PDL Proposal Form
© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.
Setting & Population

- Drug class for review: Amylin Analogs
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Documented insulin therapy regimen

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

<table>
<thead>
<tr>
<th>Laboratory Results:</th>
<th>MedWatch Form:</th>
<th>Progress Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Disposition of Edit

Denial: Exception Code “0681” (Step Therapy Edit)
Rule Type: CE

Default Approval Period

1 year

References

5. USPDI, Micromedex; 2020.
6. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

*SmartPA PDL Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.